Literature DB >> 33640299

Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.

Thomas Waddington1, Isa Mambetsariev2, Rebecca Pharaon2, Jeremy Fricke2, Angel Ray Baroz2, Hannah Romo2, Bassam Ghanem2, Stacy Gray2, Ravi Salgia3.   

Abstract

Entities:  

Keywords:  Germline mutation; Immunotherapy; NSCLC; Olaparib; Precision medicine

Mesh：

Substances：

Year:  2021        PMID： 33640299      PMCID： PMC8978804          DOI： 10.1016/j.cllc.2021.01.009

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.840


× No keyword cloud information.
  26 in total

1.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.

Authors:  Ronit I Yarden; Sherly Pardo-Reoyo; Magda Sgagias; Kenneth H Cowan; Lawrence C Brody
Journal:  Nat Genet       Date:  2002-02-11       Impact factor: 38.330

2.  [The general measurement of genetic factors on lung cancer in Xuanwei, China].

Authors:  Y Jin; X Zhou; X He
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2001-10-20

3.  Prevalence and causes of air pollution and lung cancer in Xuanwei City and Fuyuan County, Yunnan Province, China.

Authors:  Yi Cao; Huaping Gao
Journal:  Front Med       Date:  2012-05-09       Impact factor: 4.592

4.  Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.

Authors:  Tehillah S Menes; Mary Beth Terry; David Goldgar; Irene L Andrulis; Julia A Knight; Esther M John; Yuyan Liao; Melissa Southey; Alexander Miron; Wendy Chung; Saundra S Buys
Journal:  Breast Cancer Res Treat       Date:  2015-05-15       Impact factor: 4.872

5.  Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Authors:  Jung-Min Lee; Ashley Cimino-Mathews; Cody J Peer; Alexandra Zimmer; Stanley Lipkowitz; Christina M Annunziata; Liang Cao; Maria I Harrell; Elizabeth M Swisher; Nicole Houston; Dana-Adriana Botesteanu; Janis M Taube; Elizabeth Thompson; Aleksandra Ogurtsova; Haiying Xu; Jeffers Nguyen; Tony W Ho; William D Figg; Elise C Kohn
Journal:  J Clin Oncol       Date:  2017-05-04       Impact factor: 44.544

6.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.

Authors:  Shiping Jiao; Weiya Xia; Hirohito Yamaguchi; Yongkun Wei; Mei-Kuang Chen; Jung-Mao Hsu; Jennifer L Hsu; Wen-Hsuan Yu; Yi Du; Heng-Huan Lee; Chia-Wei Li; Chao-Kai Chou; Seung-Oe Lim; Shih-Shin Chang; Jennifer Litton; Banu Arun; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Clin Cancer Res       Date:  2017-02-06       Impact factor: 12.531

7.  Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States.

Authors:  A H Wu; E T Fontham; P Reynolds; R S Greenberg; P Buffler; J Liff; P Boyd; P Correa
Journal:  Am J Epidemiol       Date:  1996-03-15       Impact factor: 4.897

8.  Tumour lineage shapes BRCA-mediated phenotypes.

Authors:  Philip Jonsson; Chaitanya Bandlamudi; Michael L Cheng; Preethi Srinivasan; Shweta S Chavan; Noah D Friedman; Ezra Y Rosen; Allison L Richards; Nancy Bouvier; S Duygu Selcuklu; Craig M Bielski; Wassim Abida; Diana Mandelker; Ozge Birsoy; Liying Zhang; Ahmet Zehir; Mark T A Donoghue; José Baselga; Kenneth Offit; Howard I Scher; Eileen M O'Reilly; Zsofia K Stadler; Nikolaus Schultz; Nicholas D Socci; Agnes Viale; Marc Ladanyi; Mark E Robson; David M Hyman; Michael F Berger; David B Solit; Barry S Taylor
Journal:  Nature       Date:  2019-07-10       Impact factor: 49.962

9.  Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.

Authors:  Magdalena Koczkowska; Monika Zuk; Adam Gorczynski; Magdalena Ratajska; Marzena Lewandowska; Wojciech Biernat; Janusz Limon; Bartosz Wasag
Journal:  Cancer Med       Date:  2016-05-11       Impact factor: 4.452

10.  Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.

Authors:  Fatima Karzai; David VanderWeele; Ravi A Madan; Helen Owens; Lisa M Cordes; Amy Hankin; Anna Couvillon; Erin Nichols; Marijo Bilusic; Michael L Beshiri; Kathleen Kelly; Venkatesh Krishnasamy; Sunmin Lee; Min-Jung Lee; Akira Yuno; Jane B Trepel; Maria J Merino; Ryan Dittamore; Jennifer Marté; Renee N Donahue; Jeffrey Schlom; Keith J Killian; Paul S Meltzer; Seth M Steinberg; James L Gulley; Jung-Min Lee; William L Dahut
Journal:  J Immunother Cancer       Date:  2018-12-04       Impact factor: 13.751
View more
  1 in total

1.  A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers.

Authors:  Tingting Du; Zhihui Zhang; Jie Zhou; Li Sheng; Haiping Yao; Ming Ji; Bailing Xu; Xiaoguang Chen
Journal:  Front Pharmacol       Date:  2022-07-13       Impact factor: 5.988
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.